The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease
- 21 December 2012
- journal article
- research article
- Published by SAGE Publications in Lupus
- Vol. 22 (1), 81-86
- https://doi.org/10.1177/0961203312468624
Abstract
Background While cyclophosphamide (CYC) can save the life of a young woman with severe rheumatologic disease, it may lead to the long-term side-effects of infertility and premature menopause. We compared the reproductive health histories of young women with rheumatologic disease with and without prior CYC exposure to identify the impact of this medication on this important component of health. Methods This research includes a case-series study of women diagnosed with SLE, vasculitis, and scleroderma prior to age 35. Each patient completed a questionnaire about desired childbearing, menstrual regularity, infertility, and pregnancy history. Women with prior CYC therapy were queried about the use of gonadotropin-releasing hormone agonists (GnRH-a) for fertility preservation. The responses to this questionnaire were compared for women with and without CYC exposure. Results Of the 43 participants, 23 had prior CYC exposure and 20 were CYC naïve. The current age of these groups was similar (average age 32), but women with prior CYC were four years younger at diagnosis than women without CYC. More women with prior CYC had cessation of menses in the year prior to the study (30.4% vs 0%, p < 0.05). Of the women with prior CYC exposure, those with loss of menses were older at study enrollment, older at CYC treatment, and had a higher cumulative CYC dose than those with preserved menstruation. While more women with GnRH-a co-therapy during CYC had maintained menses, this difference did not reach statistical significance. Women with prior CYC without GnRH-a co-therapy had a higher frequency of nulliparity and had greater trouble conceiving than women with GnRH-a co-therapy. Few pregnancies were conceived following CYC exposure and all resulted in elective termination, miscarriage, or preterm birth. Conclusion In this cohort of young women with rheumatologic disease, more women with prior CYC than without had amenorrhea, nulliparity, and infertility. GnRH-a co-therapy may prevent these adverse effects of CYC.This publication has 17 references indexed in Scilit:
- Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysisBreast Cancer Research and Treatment, 2010
- Ovarian Preservation by GnRH Agonists during Chemotherapy: A Meta-AnalysisJournal of Women's Health, 2009
- Menstrual and hormonal alterations in juvenile systemic lupus erythematosusLupus, 2009
- GnRH-agonists in fertility preservationCurrent Opinion in Endocrinology, Diabetes and Obesity, 2008
- GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapyHuman Reproduction Update, 2008
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusThe New England Journal of Medicine, 2005
- Secondary Amenorrhea After Hodgkin’s Lymphoma Is Influenced by Age at Treatment, Stage of Disease, Chemotherapy Regimen, and the Use of Oral Contraceptives During Therapy: A Report From the German Hodgkin’s Lymphoma Study GroupJournal of Clinical Oncology, 2005
- Use of a gonadotropin‐releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupusArthritis & Rheumatism, 2005
- Ovarian failure and flares of systemic lupus erythematosusArthritis & Rheumatism, 1999
- Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide.Annals Of The Rheumatic Diseases, 1996